Evotec and BMS Secure Second FDA IND Acceptance
Hamburg, Germany, November 19, 2026 Evotec SE and Bristol Myers Squibb (BMS) have announced a significant milestone in their...
AI drug discovery artificial intelligence Autoimmune Disease biologics biopharma Biopharmaceuticals Biotechnology Bispecific Antibody Cancer Immunotherapy Cancer Research cancer therapy Cancer Treatment Cell Therapy Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development Drug Discovery EMA FDA fda approval FDA clearance Gene Therapy healthcare technology Immuno-Oncology immunology Immunotherapy Medical Devices MedTech Monoclonal Antibody Neurology Oncology Orphan Drug Phase 1 trial Phase 2 Trial Phase 3 Phase 3 Clinical Trial Phase 3 trial Precision Medicine Precision Oncology rare disease solid tumors targeted therapy
Hamburg, Germany, November 19, 2026 Evotec SE and Bristol Myers Squibb (BMS) have announced a significant milestone in their...
Dover, Delaware, United States, November 9, 2026 Eilean Therapeutics, LLC, a clinical-stage biotechnology company developing targeted protein degraders, has...
NEW HAVEN, Conn. — September 28, 2026 Arvinas, Inc. announced that the first participant has been dosed in the...
WILMINGTON, Del. — September 10, 2026 Prelude Therapeutics Incorporated announced that the U.S. Food and Drug Administration (FDA) has...
BOSTON, Massachusetts — September 8, 2026 Monte Rosa Therapeutics, Inc. announced that Novartis has initiated a global Phase 2...
South San Francisco, California, August 13, 2026 Rigel Pharmaceuticals, Inc. announced the U.S. commercial availability of VEPPANUâ„¢ (vepdegestrant) for...
NEW YORK and WALTHAM, Mass., August 4, 2026 Dianthus Therapeutics, Inc. announced the launch of DNTH312, an internally developed...
BRISBANE, Calif., August 4, 2026 Nurix Therapeutics, Inc. announced it has earned a $10 million development milestone payment after...
NEW HAVEN, Conn., July 27, 2026 Biohaven Ltd. and Yale University have secured a significant legal victory after a...
BOSTON, Mass., September 15, 2025 – Monte Rosa Therapeutics, Inc. (Nasdaq: GLUE), a clinical-stage biotechnology company pioneering molecular glue...
